VanEck Rare Earth/Strategic Metals vs Zoetis Inc — how do they compare? VanEck Rare Earth/Strategic Metals trades at $60.99 (market cap $1.75B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 17.3× VanEck Rare Earth/Strategic Metals's market cap, and Zoetis Inc pays a 2.9% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 50 Days and Zoetis Inc for 70 Days on average.
| REMX | ZTS | |
|---|---|---|
Market Cap | $1.75B | $30.20B |
Volume | 930,523 | 6,175,327 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $147.53 |
52-Week Low | $60.58 | $69.09 |
Typical Hold Time | 50 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $61.00, down 1.42% with a bearish technical signal. The ETF shows extreme oversold conditions with RSI readings near 14, while ADX indicates a strong downtrend. Recent news highlights strategic importance of rare earth metals amid U.S. efforts to reduce dependence on China, though individual holdings like Critical Metals show volatile performance. Bank of America increased its position by 72.1% in the latest quarter, holding 427,651 shares as of August 2026.
The outlook remains challenged by high volatility and China export controls, but strategic positioning for supply chain independence offers long-term potential. Investors face significant price swings with 50% annualized volatility, requiring risk tolerance. The bearish technical setup suggests caution near-term despite oversold conditions.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
Latest headlines on both assets
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →